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ABSTRACT 
Arginase inhibitor attenuates oxidative stress,  
inflammation, and lung injury caused by  
pneumoperitoneum in rats 
 
Jin Sun Cho 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Sungwon Na) 
 
 Pneumoperitoneum-induced oxidative stress and organ injury are known to 
be associated with nitric oxide (NO) inactivation. Because arginase competes with 
NO synthase (NOS) for a common substrate, L-arginine, arginase inhibition may 
increase NO bioavailability. Therefore, we evaluated the ability of the arginase 
inhibitor, 2(S)-amino-6-boronohexanoic acid (ABH), to attenuate pneumoperitoneum-
induced decrease of NO bioavailability and lung injury. Thirty rats were randomly 
divided into the following groups: 1) the PP-ABH group received a subcutaneous 
injection of ABH (5 mg/kg) 1 h before induction of pneumoperitoneum (insufflation 
to intraperitoneal pressure of 15 mmHg for 60 min); 2) the PP group received saline 
by subcutaneous injection 1 h before induction of pneumoperitoneum; and 3) the 
control group received saline by subcutaneous injection before a sham procedure with 
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no gas insufflation. After desufflation, blood was collected to determine levels of 
plasma nitrite, NOS, inflammatory cytokines, and malondialdehyde, a marker of 
oxidative stress. Lung tissue was obtained for histological evaluation. We found that 
plasma nitrite levels were lower in the PP group and higher in the PP-ABH group 
compared with controls. In the PP group, endothelial NOS activity was decreased and 
inducible NOS activity was increased compared with the PP-ABH and control groups. 
Malondialdehyde levels increased 3-fold in the PP group and 2-fold in the PP-ABH 
group compared with controls. Tumor necrosis factor-α, interleukin-6, and 
interleukin-1ß levels were elevated in the PP group compared to the control group, but 
the increase in cytokine production was attenuated or blocked in the PP-ABH group. 
Lung injury scores were 4.8-fold higher in the PP group and 2-fold higher in the PP-
ABH group compared with controls. By increasing NO bioavailability and 
suppressing oxidative stress and inflammation, pretreatment with an arginase inhibitor 
may protect against pneumoperitoneum-induced organ injury during laparoscopic 
surgery. 
 
 
 
 
 
------------------------------------------------------------------------------------------------------------------ 
Key Words: pneumoperitoneum, nitric oxide, arginase, oxidative stress, inflammation, 
lung injury 
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I. INTRODUCTION 
Compared with conventional open surgery, minimally invasive surgery (e.g., 
laparoscopic and robotic surgery) has considerable advantages including less pain, 
shorter hospital stays, decreased morbidity, and more rapid return to full activity.1 
However, laparoscopic surgery is not without physiologic derangement of internal 
organs. Pneumoperitoneum required for laparoscopic visualization results in 
significantly decreased blood flow to intraperitoneal organs, which promotes 
anaerobic metabolism leading to lactic acidosis, oxidative stress, and postoperative 
manifestations, such as oliguria and elevated liver enzymes.2 In addition, altered 
postoperative organ function is the major cause of laparoscopy-associated morbidity 
and mortality.3 Even short periods of pressure as low as 10–15 mmHg cause organ 
hypoperfusion, leading to postoperative tissue injury.4-6 More serious concerns have 
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been raised about robot-assisted surgery, because it requires steep or reverse 
Trendelenburg positions, which are associated with higher risks of organ damage due 
to changes in intraperitoneal pressure.2 
Mechanisms of organ injury during pneumoperitoneum include decreased nitric 
oxide (NO), sympathetic hyperactivation, and oxidative stress.7-9 Endothelial NO 
synthase (eNOS) produces most of the NO in the vasculature, where it activates 
soluble guanylyl cyclase and increases cyclic guanosine monophosphate levels in 
smooth muscle cells to dilate blood vessels.10 In addition, NO inhibits platelet 
aggregation and suppresses vascular smooth muscle hyperplasia and its sensitivity to 
the sympathetic nerve activity.11,12 Therefore, decreased NO bioavailability directly 
causes vasoconstriction and indirectly inhibits vasodilation via the autonomic nervous 
system, resulting in increase in oxidative stress and ischemic damage of not only the 
intraperitoneal organ but the extraperitoneal organ as well.8 
Because eNOS competes with arginase for the substrate L-arginine, arginase 
inhibition has the potential to increase NO bioavailability.13 The relationship between 
arginase inhibition and enhanced NO production has been demonstrated in animal 
studies using an arginase inhibitor or arginase knock-out model.14 We reasoned that 
the deleterious effects of pneumoperitoneum on tissue perfusion could be attenuated 
by improving NO bioavailability. Specifically, we hypothesized that administration of 
an arginase inhibitor before pneumoperitoneum would increase NO bioavailability, 
thereby attenuating the pneumoperitoneum-induced lung injury. We tested our 
hypothesis by evaluating plasma nitrite, oxidative stress marker, inflammatory 
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cytokines, and lung injury in a rat model during carbon dioxide (CO2) 
pneumoperitoneum with or without pretreatment with the arginase inhibitor 2(S)-
amino-6-boronohexanoic acid (ABH). 
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II. MATERIALS AND METHODS 
 
1. Animals and experimental design 
This study was approved by the Yonsei University Institutional Animal Care 
and Use Committee and was conducted according to the established guiding 
principles for animal research. All experiments were performed in 3- to 4-month-old 
male Sprague–Dawley rats weighing 250–320 g. The rats were housed individually, 
maintained at a constant temperature and humidity under a 12-h dark/light cycle, and 
allowed food and water ad libitum. The rats were randomly divided into three groups, 
each consisting of 10 rats: 1) the PP-ABH group received a subcutaneous injection of 
ABH (5 mg/kg) 1 h before induction of pneumoperitoneum; 2) the PP group received 
a subcutaneous injection of saline 1 h before induction of pneumoperitoneum; and 3) 
the control group received saline only (pneumoperitoneum was not induced).  
 
2. Pneumoperitoneum 
One hour after injection of ABH or saline, the rats were anesthetized with 
inhaled sevoflurane and secured a supine position on a thermostatically regulated 
heating pad (37°C). After tracheostomy the lungs were mechanically ventilated with a 
volume-driven small-animal ventilator (model 665A, Harvard Apparatus, Holliston, 
MA, USA). Tidal volume was set 1 mL/100 g body weight, and respiratory rate was 
adjusted to 55–60 breaths/min to maintain end-tidal CO2 at 30–35 mmHg. Anesthesia 
was maintained with 1.5%–2.0% (volume percent) sevoflurane and 50% oxygen in air. 
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A Veress needle was then inserted in each rat. The control group underwent a sham 
procedure with no gas insufflation, maintaining intra-abdominal pressure at 0 mmHg. 
To induce pneumoperitoneum in the PP and PP-ABH groups, CO2 was insufflated 
using an electronic laparoflator (Karl Storz GmbH, Tuttlingen, Germany), 
maintaining intra-abdominal pressure at 15 mmHg. After 1 h of pneumoperitoneum or 
sham procedure, heparin was administered, and the rats were euthanized by cervical 
dislocation. Blood and lung tissue were obtained for analysis. 
 
3. Western blotting analysis for expression of NOS and arginase II 
Lung tissue specimens were thawed and homogenized in ice-cold protein 
extraction buffer (Pro-prep, Intron Biotechnology, Seoul, Korea). The protein samples 
were separated by 8%–10% SDS-polyacrylamide gel electrophoresis, and then 
transferred to a 0.2-μm polyvinyl-difluoride membrane (Immun-Blot, Bio-Rad, 
Hercules, CA, USA). The membranes were blocked using 5% (wt/vol) nonfat milk in 
Tris-buffered saline with 0.1% Tween-20, and then incubated overnight at 4°C with 
polyclonal antibodies (1:1000 dilution) against inducible NOS (iNOS; Abcam®, 
Cambridge, UK), eNOS (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and Arg 
II (Santa Cruz Biotechnology). The bound antibody was detected with labeled anti-
rabbit secondary antibodies (1:5000 dilution) and visualized using the ECL Plus 
chemiluminescence assay (Amersham Biosciences, Piscataway, NJ, USA). Protein 
expression was normalized to β-actin (1:1000 dilution).  
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4. Arginase assay for arginase II activity  
Activity of intracellular arginase was determined using the QuantiChromTM 
arginase assay kit (BioAssay Systems, Hayward, CA, USA), which measures the 
conversion of arginine to urea by arginase. Lung tissue was sonicated for 10 min in 
lysis buffer (50 mmol Tris-HCl, pH 7.5, 0.1 mmol EDTA, 0.1% Triton X-100, and 
protease inhibitor) and centrifuged for 30 min at 14,000 × g at 4°C. The supernatant 
(50 μL) was added to 75 μl Tris-HCl (50 nmol, pH 7.5) containing 10 mmol MnCl2, 
and the mixture was activated by heating at 55°C–60°C for 10 min. The mixture was 
incubated with 50 μL L-arginine (0.5 M, pH 9.7) at 37°C for 2 h, and the reaction was 
stopped by adding 400 μL acid solution (H2SO4:H3PO4:H2O, 1:3:7). For the 
colorimetric determination of urea, 25 μL α-isonitrosopropiophenone (9% in ethanol) 
was added, and the mixture was heated at 100°C for 45 min. After holding the 
reaction mixture in the dark for 10 min at room temperature, the urea concentration 
was determined spectrophotometrically by measuring absorbance at 430 nm.  
 
5. Griess nitrite assay 
To measure plasma nitrite (NO2-), blood was collected in tubes containing 
anticoagulants (citrate and EDTA). The tubes were centrifuged for 15 min at 1000 × g, 
and the plasma was incubated with 100 μL Griess reagent (1% sulfanilamide in 
0.1 mol/l of HCl and 0.1% N-(1-naphthyl) ethylene diamine dihydrochloride) (Sigma-
Aldrich, St. Louis, MO, USA) at room temperature for 10 min. Absorbance at 540 nm 
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was measured using a microplate reader, and nitrite content was calculated based on a 
standard curve constructed using NaNO2. 
 
6. Enzyme-linked immunosorbent assay for NOS activity 
The activities of eNOS and iNOS were determined using rat eNOS and 
iNOS enzyme-linked immunosorbent assay (ELISA) kits (Yuhan EIAab science, 
Korea). In brief, lung tissue specimens were homogenized in ice-cold Pro-Prep, and 
the supernatant was incubated in a 96-well plate containing co-factors and the 
substrate L-arginine at 37°C. After 1 h, the reaction was quenched by adding the stop 
buffer. The concentrations of nitrites and nitrates in the reaction mixture were 
determined using a colorimetric method (530 nm). 
 
7. ELISA for oxidative stress marker malondialdehyde 
To assess oxidative stress in the lung tissue, we evaluated malondialdehyde 
(MDA), which is a stable product of lipid peroxidation that is used as an index of 
oxygen free radical production. The MDA content in lung tissue was measured using 
an OxiSelectTM MDA Adduct ELISA kit (Cell Biolabs, Inc., San Diego, CA, USA). 
After adding the stop solution to halt the enzymatic reaction, absorbance at 450 nm 
was measured using a spectrophotometer .  
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8. ELISA for proinflammatory cytokines  
Commercially available ELISA kits were used to determine serum levels of 
tumor necrosis factor (TNF)-α (BD Biosciences, San Jose, CA, USA), interleukin 
(IL)-1β (eBioscience, San Diego, CA, USA), and IL-6 (Young In Frontier Co., Ltd., 
Korea). In brief, supernatants of lung tissue were added to a 96 well plate coated with 
corresponding antibodies to each cytokine and incubated. Streptavidin-horseradish 
peroxidase conjugate was added as an antibody to a second epitope on each cytokine. 
Absorbance was read by a microplate reader using 450 nm as the primary wave length 
after adding the stop solution. 
 
9. Lung histology 
Lung tissue specimens obtained from the left lower lobe were fixed with 3% 
paraformaldehyde, embedded in paraffin, and then stained with hematoxylin and 
eosin. Lung injury was assessed by a pulmonologist, who was blind to the group 
allocation using the modified scoring system described by Kristof et al..15 The level of 
lung injury was graded as none (0), mild (1), moderate (2), or severe (3) for each of 
the following three categories: interstitial cellular infiltration, alveolar protein 
exudation, and tissue hemorrhage. For each rat, 10 microscopic fields were randomly 
selected (200× magnification). The score for each category was determined by adding 
the scores from the 10 different microscopic fields, and the total lung injury score for 
each rat was calculated as a sum of the three category scores.  
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10. Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). Groups 
were compared by one-way analysis of variance for multiple comparisons (Tukey’s 
post hoc test). Nonparametric data were analyzed by chi-square test. Statistical 
analysis was conducted using Prism 5.01 software (GraphPad software Inc. CA, 
USA); P < 0.05 was considered significant.  
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III. RESULTS 
1. Arginase II expression and activity 
Results of western blot analysis showed that arginase II expression in the 
lung tissue was comparable among the three groups of rats (Figure 1A). However, 
arginase II activity was significantly higher in rats that underwent pneumoperitoneum 
(PP group) compared with those pretreated with ABH before pneumoperitoneum 
induction (PP-ABH group) and untreated controls (1.70 ± 0.60 U/L vs. 0.72 ± 0.25 
U/L and 0.56 ± 0.31 U/L, respectively, P < 0.01 in both) (Figure 1B).  
 
 
Figure 1. Arginase II expression and activity. (A) Arginase II expression did not differ 
significantly among the treatment groups. (B) However, arginase II activity was 
increased significantly in the PP group compared with the PP-ABH and control 
groups. ** P < 0.01. 
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2. NO bioavailability 
Levels of plasma nitrite, a stable metabolite of NO, were significantly lower 
in the PP group compared with the PP-ABH and control groups (19 ± 6.1 µmol/L vs. 
60 ± 1.3 µmol/L and 42 ± 9.0 µmol/L, respectively, P < 0.001 and P < 0.01, 
respectively) (Figure 2). In addition, plasma nitrite level was higher in the PP-ABH 
group compared with the control group (P < 0.05).  
 
 
 
Figure 2. Plasma nitrite levels. Plasma nitrite, a stable metabolite of NO, was 
decreased in the PP group but increased in the PP-ABH group compared to controls. * 
P < 0.05, ** P < 0.01, *** P < 0.001 
 
 
 
 
14 
 
3. NOS expression and activity 
Results of western blot analysis showed that eNOS and iNOS levels in the 
lung tissues were comparable among the three treatment groups (Figure 3A). 
However, eNOS activity, as assessed by ELISA, was significantly lower in the PP 
group compared with the PP-ABH and control groups (2.8 ± 1.3 ng/ml vs. 14 ± 5.4 
ng/ml and 11 ± 3.5 ng/ml, respectively, P < 0.01 and P < 0.05, respectively) (Figure 
3B). Similarly, iNOS activity in the lung tissue was significantly higher in the PP 
group compared with the controls (19 ± 6.0 nmol/L vs 4.3 ± 1.9 nmol/L, P < 0.001), 
but this increase was prevented in the PP-ABH group (11 ± 3.5 nmol/L). 
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Figure 3. NOS expression and activity. (A) Expression of endothelial nitric oxide 
synthase (eNOS) and inducible nitric oxide synthase (iNOS) did not differ 
significantly among the three treatment groups. (B) However, eNOS activity was 
significantly lower and iNOS activity was higher in the PP group compared with the 
PP-ABH and control groups. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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4. Oxidative stress 
Results of ELISA showed that MDA content in lung tissue was higher in the 
PP and PP-ABH groups compared with the control group (50 ± 12 pmol/mg and 33 ± 
8.1 pmol/mg vs. 17 ± 5.0 pmol/mg, respectively, P < 0.001 and P < 0.05, 
respectively), with higher MDA levels observed in the PP group than in the PP-ABH 
group (P < 0.05) (Figure 4).   
 
 
 
Figure 4. Oxidative stress. Levels of the oxidative stress marker malondialdehyde 
(MDA) were increased in the PP and PP-ABH groups compared to the control group, 
and were higher in the PP group than in the PP-ABH group. * P < 0.05, *** P < 0.001. 
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5. Inflammatory cytokines 
Results of ELISA showed that TNF-α expression was higher in the PP and 
PP-ABH groups compared with controls (25 ± 5.4 pg/mL and 16 ± 5.2 pg/mL vs. 7.1 
± 2.1 pg/mL, respectively, P < 0.001 and P < 0.05, respectively), with higher TNF-α 
levels observed in the PP group than in the PP-ABH group (P < 0.05). Levels of both 
IL-6 and IL-1β were significantly higher in the PP group compared with the PP-ABH 
and control groups (Figure 5).   
 
Figure 5. Inflammatory cytokines. Serum levels of TNF-α were increased in the PP 
and the PP-ABH groups compared with the control group, and were higher in the PP 
group than in the PP-ABH group. IL-6 and IL-1β were increased significantly in the 
PP group compared with the PP-ABH and control groups. * P < 0.05, ** P < 0.01, *** P 
< 0.001 
 
6. Lung injury 
Results of histologic analysis showed increased cellularity in the PP group (P 
< 0.001) and PP-ABH group (P < 0.05) compared with controls, and cellular 
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infiltration was greater in the PP group than in the PP-ABH group (P < 0.001). 
Protein exudation was increased in the PP group compared the control (P < 0.001) and 
PP-ABH groups (P < 0.01), but the degree of hemorrhage was similar among the 
three groups. The total lung injury scores (sum of cellularity, protein exudate, and 
hemorrhage scores) were 4.8-fold higher in the PP group (P < 0.001) and 2-fold 
higher in the PP-ABH group (P < 0.01) compared to the control group. The total lung 
injury score was significantly higher in the PP group than in the PP-ABH group (P < 
0.001) (Figure 6, Table 1).  
 
 
Figure 6. Lung histology. (A) Normal lung histology in the control group after saline 
injection and sham procedure with no gas insufflation. (B) Lung tissue in the PP 
group shows inflammatory cell infiltration and protein exudation associated with 
pneumoperitoneum. (C) Pneumoperitoneum-induced inflammatory changes and 
protein exudation were attenuated in the PP-ABH group. Hemorrhage levels were 
comparable among the three treatment groups.  
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Table 1. Lung injury score. 
 
Cellularity 
Protein 
exudation 
Hemorrhage Total score 
Control 1.3 ± 0.58 0.66 ± 0.44 0.84 ± 0.36 2.9 ± 0.97 
PP 7.4 ± 1.4***   4.8 ± 1.2*** 1.4 ± 0.9  14 ± 1.4*** 
PP-ABH  3.4 ± 1.1*, ###   2.1 ± 0.93##  0.9 ± 0.43     6 ± 
1.4**, ### 
The scores of cellularity were higher in the PP and PP-ABH groups compared to the 
control group, and were higher in the PP group than in the PP-ABH group. The scores 
of protein exudation were higher in the PP group compared the control (P < 0.001) 
and PP-ABH groups (P < 0.01), but the degree of hemorrhage was similar among the 
three groups. The total lung injury scores (sum of cellularity, protein exudate, and 
hemorrhage scores) were higher in the PP (P < 0.001) and PP-ABH groups (P < 0.01) 
compared to the control group, and were higher in the PP group than in the PP-ABH 
group (P < 0.001). * P < 0.05, ** P < 0.01, *** P < 0.001 compared with controls; ## P 
< 0.01, ### P < 0.001 compared with the PP group.  
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IV. DISCUSSION  
The main finding of this study was that administration of the arginase inhibitor 
ABH attenuated the pneumoperitoneum-induced decrease in NO bioavailability in 
rats. In addition, ABH maintained the activities of eNOS and iNOS; attenuated the 
increase in levels of the oxidative stress marker MDA and inflammatory cytokines 
TNF-α, IL-6, and IL-1β; and decreased the severity of lung injury caused by 
pneumoperitoneum. 
Although pneumoperitoneum is essential for adequate visualization during 
laparoscopic surgery, the resulting derangement in organ function contributes to 
morbidity and mortality. The protective role of NO in maintaining organ function has 
been demonstrated in several studies. NO maintains the organ blood flow. Organ 
hypoperfusion during pneumoperitoneum can be attenuated by pretreatment with the 
NO substrates nitroglycerine and ethyl nitrite, but is exacerbated by administration of 
the NOS inhibitor NG-nitro-L-arginine methyl ester.6,16 In addition, NO protects the 
cardiovascular system by inhibiting norepinephrine secretion and decreasing the 
response of vascular smooth muscle to the sympathetic nervous system.12 
Furthermore, NO exerts anti-inflammatory and anti-thrombotic effects through the 
inhibition of leukocyte adhesion and platelet aggregation, thereby protecting against 
vascular diseases such as atherosclerosis.17,18 The predominant isoform of NOS is 
eNOS, which keeps blood vessels dilated, controls blood pressure, and has 
vasoprotective and anti-atherosclerotic effects.11 In contrast, iNOS is induced by 
inflammatory cytokines, and NO produced by iNOS has cytostatic effects, 
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contributing to the pathophysiology of inflammatory disease and septic shock.19 In 
this study, pneumoperitoneum led to a decrease in eNOS activity and increase in 
iNOS activity, resulting in decreased NO bioavailability.  
 By competing with NOS for the substrate L-arginase, arginase acts as a critical 
regulator of NO synthesis.20 Thus, arginase activity inhibits NO production,19 thereby 
decreasing NO levels and increasing superoxide, which can cause endothelial 
dysfunction.21 Previous studies have reported that inhibition or knock-out of arginase 
decreases atherosclerosis and protects against myocardial ischemia-reperfusion 
injury.14,22,23 Our results showed that NO bioavailability and eNOS activity were 
higher in rats that received ABH before pneumoperitoneum compared with those that 
did not receive ABH before pneumoperitoneum. It may suggest that inhibition of 
arginase activity could maintain NO bioavailability by preventing or attenuating 
pneumoperitoneum-induced changes in NOS activity. 
It is well known that pneumoperitoneum-induced organ injury occurs not only 
in the intraabdominal organs, but also in the extraabdominal organ, such as lung. 
Pneumoperitoneum-induced oxidative stress and lipid peroxidation were identified as 
components of lung injury after pneumoperitoneum. The decrease of antioxidant 
renders cells or tissues more susceptible to reactive oxygen species attack24 and lipid 
peroxidation results in the damage of biological membrane and therefore cell damage 
and tissue injury.25 In addition, abdominal deflation at the end of a laparoscopic 
procedure provides a model of reperfusion damage in previously ischemic organs, 
aggravating the oxidative stress and lipid peroxidation.26 Even when 
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pneumoperitoneum was maintained at low pressure of 6 mmHg for 20 min, MDA and 
oxidatively modified proteins were increased in the lung in rats.25 With CO2 
pneumoperitoneum maintained at 15 mmHg for 30 min, intra-alveolar hemorrhage, 
dense congestion, and leukocyte infiltration were found in the lungs in rats.27 In 
addition, pneumoperitoneum increases the inflammation cytokine,9 which leads to the 
release of local mediators such as platelet-activating factors and reactive oxygen 
species, which cause damage to cell structures, capillary endothelium, and pulmonary 
tissue, resulting in lung injury.28 Consistent with these previous findings, the levels of 
the oxidative stress marker MDA and inflammatory cytokines were increased by 
pneumoperitoneum in this study. Administration of a drug with anti-oxidant and anti-
inflammatory effects was demonstrated to reduce the severity of pneumoperitoneum-
associated lung injury.27,29 In this study, the pretreatment of arginase inhibitor before 
pneumoperitoneum partially or completely blocked the increase of oxidative stress 
and inflammation, and these anti-oxidant and anti-inflammatory effects might 
contribute to the decrease of lung injury.  
As another possible mechanism to reduce lung injury, arginase inhibitor reduced 
iNOS activity. Oxidative stress is resulted from overproduction of reactive oxidative 
species, such as superoxide anion (O2
-), which inactivates NO and diminishes its 
protective function.30 Although NO protects against lung injury by inhibiting 
neutrophil migration and NF-κB activity,31,32 excessive NO production by iNOS is 
associated with the development of lung injury in septic condition.33,34 In our results, 
the increased NO bioavailability and attenuated iNOS activity induced by the arginase 
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inhibitor likely contribute to the reduction in lung injury. 
This study has several limitations. Firstly, we decided the abdominal pressure at 
15 mmHg, which was previously reported to induce oxidative injury in lung tissue in 
rats.8,27 In human, insufflation pressure is generally set at less than 12 mmHg, not to 
raise the intraabdominal pressure above that of the normal portal circulation pressure. 
Especially in surgical intensive care units, intra-abdominal pressure is tried to be 
maintained less than 12 mmHg to prevent abdominal compartment syndrome, where 
the detrimental effects of increased intra-abdominal pressure are frequently 
observed.35 In this study, intraabdominal pressure was set at a higher level than usual 
to find out the effect of arginase inhibitor on pneumoperitoneum-induced organ injury. 
Further study is needed to evaluate the effect of arginase inhibitor on the lung injury 
in a sequential manner according to the level of abdominal pressure. Secondly, 
although all study groups received mechanical ventilation with the same setting, 
elevated intraabdominal pressure might displace the diaphragm in a cephalad 
direction and increase intrathoracic pressure in the pneumoperitoneum-induced 
groups, which might influence lung injury. Thirdly, in addition to arginase and NOS, 
agmatine was reported to involve in the arginine-dependent pathways.36 Agmatine is 
decarboxylated arginine, and thus agmatine biosynthesis competes with nitrogen 
metabolism by arginase and NO synthesis by NOS. Agmatine is induced in response 
to stress and/or inflammation and modulates NO synthesis by inhibition of neuronal 
NOS and iNOS and induction of eNOS. Further research is needed to elucidate the 
change of agmatine and the interaction among agmatine, NOS and arginase during 
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pneumoperitoneum. 
 
V. CONCLUSION 
In conclusion, our results show that pneumoperitoneum led to a decrease in 
eNOS activity and increase in iNOS activity, which might contribute to decreased NO 
bioavailability. Pretreatment with the arginase inhibitor, ABH, prevented these 
changes, and partially or completely blocked pneumoperitoneum-induced oxidative 
stress and inflammation, and decreased the severity of lung injury. Although these 
findings are not applicable to clinical practice, they indicate the potential of arginase 
inhibitors in reducing pneumoperitoneum-associated organ injury in laparoscopic 
surgery.  
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ABSTRACT (IN KOREAN) 
Arginase inhibitor 가 백서에서 기복으로 발생하는  
산화 스트레스, 염증 및 폐 손상에 미치는 영향 
 
<지도교수 나 성 원> 
연세대학교 대학원 의학과 
조 진 선 
 
 복강경 수술을 개복 수술에 비해 통증이 적고 회복이 빠른 등 많
은 장점이 있어 개복 수술을 대체하여 왔으며, 로봇 수술 등으로 그 범위
가 더욱 확대되고 있다. 하지만 시야를 확보하기 위해 시행하는 기복으로 
인해 장기 혈류가 감소하고 산화 스트레스의 증가, 염증, 장기 손상 등이 
발생하여 환자의 예후에 영향을 미친다. 기복으로 인해 발생하는 산화 스
트레스와 장기 손상에 산화 질소의 불활성화가 관련된 것으로 알려져 있다. 
Arginase와 산화 질소 합성효소는 L-arginine을 기질로 공유하기 때문에, 
arginase가 활성화되면 산화 질소의 생성이 감소되고 그 생체가용성이 떨
어지는 것으로 알려져 있다. 본 연구의 목적은 arginase 억제제인 2(S)-
amino-6-boronohexanoic acid (ABH)을 투여하여 기복으로 인해 발생하
는 산화 질소의 생체가용성 감소 및 폐 손상에 미치는 영향을 알아보고자 
31 
 
했다.  
 30마리의 쥐를 각각 10마리씩 무작위로 세 군으로 배정하였다. <
기복-arginase 억제제군>에서는 arginase 억제제를 투여한 뒤 복압 15 
mmHg로 1시간 동안 기복을 시행하였다. <기복군>에서는 arginase 억제제 
대신 생리 식염수를 투여한 뒤 같은 방법으로 기복을 시행하였다. <대조군
>에서는 생리 식염수를 투여하고 복벽을 천자한 후 복압 0 mmHg로 1시
간 동안 유지하였다. 기복 해제 후, 혈장과 폐 조직 샘플을 채취하여 아질
산염, 산화 질소 합성효소, 산화 스트레스 지표 및 염증 사이토카인을 측정
하였다. 혈장 아질산염은 기복군에서 대조군과 기복-arginase 억제제군에 
비해 감소하였다. 기복군에서는 산화 질소 합성효소 중 endothelial NOS는 
감소하고 inducible NOS는 증가하였으나, 기복-arginase 억제제군은 대조
군과 같은 산화 질소 합성효소 활성을 유지하였다. 산화 스트레스의 지표
인 malondialdehyde는 기복군에서는 대조군의 3배로 증가하였으나, 기복-
arginase 억제제군에서는 대조군의 2배로 그 증가 정도가 감소하였다. 염
증 사이토카인인 Tumor necrosis factor-α, interleukin-6, interleukin-1ß
은 기복군에서는 대조군에 비해 증가하였으나, 기복-arginase 억제제군에
서는 그 증가 정도가 감소하거나 대조군과 비슷한 수준을 보였다. 폐 손상 
정도는 대조군에 비해 기복군이 4.8배, 기복-arginase 억제제군은 2배를 
보였다.  
본 연구 결과, arginase 억제제를 투여하면 기복으로 인한 산화 스
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트레스와 염증의 발생을 줄이고 산화 질소의 가용성을 유지할 수 있었으며, 
이와 함께 폐 손상도 줄일 수 있었다. 본 연구를 통하여 기복으로 인한 장
기 손상 기전에 대한 이해와, 복강경 수술 시 장기 손상을 줄이는 예방법
을 제시하는데 도움을 줄 수 있을 것으로 사료된다. 
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